Trial Profile
Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy Adult
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Hantaan virus vaccine-(Hantavax) (Primary) ; Hantaan virus vaccine-(Hantavax) (Primary)
- Indications Hantaan virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GC Biopharma
- 29 Oct 2020 Results evaluating the immunogenicity and safety of Hantavax when administered by the revised 3 + 1 vaccination schedule published in the Vaccine
- 01 Feb 2016 Status changed from not yet recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 23 Sep 2015 New trial record